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Abstract
Background A campaign to increase the awareness of the
signs and symptoms of colorectal cancer (CRC) and
encourage self-presentation to a GP was piloted in two
regions of England in 2011. Short-term data from the pilot
evaluation on campaign cost and changes in GP attendances/
referrals, CRC incidence, and CRC screening uptake were
available. The objective was to estimate the effectiveness
and cost-effectiveness of a CRC awareness campaign by
using a mathematical model which extrapolates short-term
outcomes to predict long-term impacts on cancer mortality,
quality-adjusted life-years (QALYs), and costs.
Methods A mathematical model representing England
(aged 30?) for a lifetime horizon was developed. Long-
term changes to cancer incidence, cancer stage distribution,
cancer mortality, and QALYs were estimated. Costs were
estimated incorporating costs associated with delivering
the campaign, additional GP attendances, and changes in
CRC treatment.
Results Data from the pilot campaign suggested that the
awareness campaign caused a 1-month 10 % increase in
presentation rates. Based on this, the model predicted the
campaign to cost £5.5 million, prevent 66 CRC deaths and
gain 404 QALYs. The incremental cost-effectiveness ratio
compared to ‘‘no campaign’’ was £13,496 per QALY.
Results were sensitive to the magnitude and duration of the
increase in presentation rates and to disease stage.
Conclusions The effectiveness and cost-effectiveness of a
cancer awareness campaign can be estimated based on
short-term data. Such predictions will aid policy makers in
prioritizing between cancer control strategies. Future cost-
effectiveness studies would benefit from campaign evalu-
ations reporting as follows: data completeness, duration of
impact, impact on emergency presentations, and compari-
son with non-intervention regions.
Keywords Colorectal cancer  Awareness campaign 
Early diagnosis  Cost-effectiveness
What is already known on this subject
Numerous primary studies have provided evidence about
the impact of colorectal cancer awareness campaigns on
public knowledge of campaign, knowledge of signs and
symptoms, attitudes toward disease and treatment and
behavior in terms of presentation to a GP, and uptake of
screening. Until now, only one interim analysis of a pri-
mary study has provided evidence on effectiveness in terms
of ‘‘change in cancer incidence’’ and no studies have
reported data on mortality or cost-effectiveness.
What this study adds
Our study demonstrates that it is possible to use a mathe-
matical model in combination with short-term data from an
awareness campaign to predict effectiveness (change in
incidence and mortality) and cost-effectiveness (cost per
quality-adjusted life-year).
Our study predicts that a national colorectal cancer
awareness campaign in England would prevent 66 cancer
deaths (based on data from the pilot awareness campaign).
Our study highlights key outcomes to report in the
evaluation of future awareness campaigns, for example
duration of campaign impact.
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University of Sheffield, Sheffield, UK
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Introduction
Cancer survival rates in England are poor compared to
several other European countries, and there is increasing
recognition that a considerable proportion of these avoid-
able deaths relate to late diagnosis [1, 2]. A National
Awareness and Early Diagnosis Initiative (NAEDI) has
been established in England as part of the Government’s
strategy to improve cancer outcomes with one work
stream, specifically focussing on raising public awareness
and promoting earlier presentation by patients [3].
The National Cancer Action Team has been running a
series of cancer awareness campaigns since 2009. The
primary aim of cancer awareness campaigns is earlier
presentation of symptomatic cancers through improved
public knowledge of the symptoms [4]. Earlier presentation
can result in cancers being diagnosed in earlier stages
which may be associated with better survival and reduced
treatment costs. However, a campaign may also lead to
increased numbers of GP attendances by the ‘‘worried
well’’; indeed some critics assert that the campaigns will
‘‘undo years of work persuading patients with minor ail-
ments to stay at home’’ [5]. Figure 1 summarizes the
potential impacts of a colorectal cancer (CRC) awareness
campaign.
A systematic review of available evidence on CRC
awareness campaigns demonstrated that most studies
focused on short-term outcomes such as ‘‘change in
awareness’’ or ‘‘change in behavior’’ rather than longer-
term outcomes such as ‘‘change in cancer incidence or
mortality’’ [6]. Existing studies do not provide evidence of
the mortality reduction associated with cancer awareness
campaigns, few costs are reported, and no estimates of
cost-effectiveness are available [6]. Collection of data on
CRC mortality reduction following an awareness campaign
would actually be unfeasible to collect as: (1) a long time-
frame would be required; (2) a very large population would
be required to demonstrate a statistically significant small
change; and (3) it may be difficult to prove that any change
can be attributed to the campaign rather than other factors.
In January 2011, a CRC ‘‘signs and symptoms’’ cam-
paign was piloted in two regions of England and an eval-
uation was produced by the Department of Health [7]. We
present estimates of the effectiveness and cost-effective-
ness of a CRC awareness campaign which are generated
using a mathematical model together with short-term data
from this pilot campaign. Effectiveness is measured in
terms of change in CRC incidence, CRC mortality, and
quality-adjusted life-years (QALYs). Cost-effectiveness is
measured as cost per QALY, incorporating the cost of the
campaign, the cost of additional GP attendances, any
change in CRC treatment costs, and QALYs accrued. The
estimates provide an improved understanding of the ben-
efits of such a campaign, which can be used to inform
change in 
costs & 
QoL
Fig. 1 Potential effects of an
early awareness campaign for
colorectal cancer (CRC)
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policy decisions around the selection of initiatives for the
prevention of cancer morbidity and mortality.
Methods
Pilot colorectal cancer awareness campaign
Figure 2 summarizes the key facts relating to the pilot CRC
awareness campaign. Data from the pilot campaign were
available from the pilot evaluation report (March 2012) [7].
The pilot evaluation report included campaign running
costs and data describing changes in GP attendances/
referrals, CRC incidence, and CRC screening uptake. More
recent, cancer incidence data were obtained from the South
West Public Health Observatory and the Eastern Cancer
Registration and Information Centre (October 2012) [8, 9].
Data on CRC detected at screening and screening uptake
rates were also obtained from the NHS Bowel Cancer
Screening Programme (BCSP) [10]. The data were ana-
lyzed to determine the magnitude and duration of the short-
term impacts of the campaign, and this informed the
mathematical model. The data illustrated an increase in the
number of GP attendances, secondary care appointments,
colonoscopy activity, and CRC incidence, which could be
attributed to the campaign. A summary of the pilot cam-
paign data used to inform the model is provided in Table 1.
A detailed description of the data and modeling assump-
tions for the main pilot outcomes is provided below.
GP attendances
Data on the number of GP attendances with symptoms
associated with CRC were available for a sample of
Pilot bowel cancer awareness campaign KEY FACTS
Run by: Department of Health
Regions: East of England, South West
Total population: 11 million persons
Campaign aim: To increase awareness of the signs and symptoms of bowel cancer and to 
encourage persons with symptoms to visit their GP. 
Campaign message: “If you have (1) A persistent change in normal bowel habit, such as going to 
the toilet more often and diarrhoea, especially if you are also bleeding from your back passage, or 
(2) Bleeding from the back passage without any reason, particularly over the age of 55, then it’s 
important to go and see your GP. The sooner you see your doctor to have it checked, the better.”
Duration: 7 weeks
Dates: 24th January-21st March 2011
Campaign delivery channels: regional TV, print media (regional/local press etc.), inserts into 
regional editions of national press, online, regional/ local radio, and shopping centres. A bowel 
cancer resource pack was sent to GPs and this contained detailed information for each local 
authority. 
Fig. 2 Pilot bowel cancer
awareness campaign, key facts
Table 1 Summary of data from the pilot campaign used in the modeling
Data observed from pilot campaign Base case assumption in model Scenario analyses
GP attendances 700 increase over 3-month period (532
increase if diarrhea included as a
symptom)
Equivalent to 60,000–80,000 nationally.
70,000 more attendances
nationally over 3-month period
Assumed 50 % ‘‘additional’’ &
50 % ‘‘earlier’’
Assumed 90 % ‘‘additional’’ &
10 % ‘‘earlier’’
GP referrals 1956 increase in referrals over 5-month
period (?28 %)
17,519 additional referrals
nationally
Assumed 50 % ‘‘additional’’&
50 % ‘‘earlier’’
Assumed 90 % ‘‘additional’’ &
10 % ‘‘earlier’’
CRC incidence 7–11 % increase in incidence for 1 month 10 % increase in presentation rates
for 1 month
5–20 % magnitude
1 to 6-month duration
CRC incidence stage
distribution
Numbers too small to draw any
conclusions
Campaign assumed to have the
same proportional effect on
presentation rates for each CRC
stage.
Short-term increase in incidence
only consists of Dukes’ stages C
& D
CRC screening uptake No significant change which could be
attributed to the campaign
Assume screening uptake
unaffected by campaign
Exploratory analysis undertaken
Cost of running
campaign
£5 million £5 million –
Cancer Causes Control (2014) 25:647–658 649
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practices for the period January 2010 to April 2011. During
the 3-month period February to April 2011, GP attendances
for the three symptoms rectal bleed, loose stools, and
change in bowel habit increased by 700 (?62 %) and the
increase was 532 (?20 %) if diarrhea was also included as
a symptom. This would correspond to a further
60,000–80,000 GP attendance on a national scale. No
change in the gender or age distribution of patients was
evident. The increase in GP attendances was associated
with considerable uncertainty due to large variations
between practices and a possible change in symptom
coding during the period of data collection. No data were
collected for GP attendances following April 2011, so the
duration of the effect of the campaign is uncertain. In the
model, it was assumed that a national campaign would
result in a further 70,000 GP attendance. There were no
data to indicate what proportion of the increase in atten-
dances were ‘‘additional’’ as opposed to ‘‘earlier’’, so 50 %
was assumed with 90 % considered in a sensitivity
analysis.
GP referrals
Data on the number of 2-week wait referrals from GP to
secondary care with suspicion of lower gastrointestinal
cancer was available for the months February to June for
2010 and 2011. The number of referrals was seen to
increase by 1956 (?28 %) from 2010 to 2011 (corre-
sponding to a further 17,519 on a national scale). As no
data on the number of GP referrals for the period after June
2011 were available, the duration of the effect of the
campaign is uncertain. There was evidence of an increase
in colonoscopy demand and activity during the period
February to June 2011 when compared to the previous
year. The increase was estimated to be approximately
3,400 additional colonoscopies. There were no data to
indicate what proportion of the increase in referrals were
‘‘additional’’ as opposed to ‘‘earlier’’, so 50 % was
assumed with 90 % considered in a sensitivity analysis.
CRC incidence
CRC has two possible routes of diagnosis: via the national
screening program (10 % diagnosed via this route in 2010)
or via symptomatic or chance presentation [10]. Data on
monthly CRC incidence for the two pilot regions were
available for the period January 2010 to September 2011.
These data are presented in Fig. 3. As the campaign started
at the end of January 2011, it was assumed that no change
in incidence would be expected until March 2011 due to
the likely time delay between making a GP appointment
and receiving a diagnosis. A t test was undertaken to see
if the cancer incidence observed in March 2011 was
statistically significantly different compared to the pro-
ceeding period (January 2010 to February 2011). The
pooled data set for the two regions had a p-value of less
than 0.005, suggesting that an increase did occur in March
2011. The incidence for March 2011 was 11 % higher than
that seen in March 2010 and 7 % higher than the mean
?2sd for the period January 2011 to January 2012. No
significant increase in incidence was observed for the
period April 2011 onwards, using a threshold p-value of
0.01. Data on screen-detected CRC did not show any
relationship with the awareness campaign [10]. The mod-
eling assumes that the pilot campaign led to an increase in
symptomatic detected incidence of 10 % for a period of
1 month only. Data on CRC incidence by Dukes’ stage at
diagnosis involved very small numbers, so it was not
possible to draw any significant conclusions regarding the
impact of the campaign on the stage distribution.
There is considerable uncertainty surrounding the
assumption that the pilot campaign caused an increase in
incidence for the following three reasons. When the data
from the individual regions were considered separately,
there was more uncertainty: the p-values were 0.109 for the
southwest data, 0.001 for the East of England data and
0.002 for the pooled data set. The analysis assumed that
similar incidence would be expected in 2010 and 2011, but
no data from a region not participating in the pilot were
available to test this assumption. Monthly variations in
incidence may occur as a result of factors such as different
length months, different numbers of clinics, and different
numbers of working days.
CRC screening uptake
Data on uptake of screening during the period January
2010 to November 2011 were available from the BCSP for
the two regions covered by the pilot [10]. An increase in
overall uptake was observed during the campaign period;
however, further data analysis suggests, this may not be
 -
 100
 200
 300
 400
 500
 600
 700
 800
Ja
n-
10
Fe
b-
10
M
ar
-1
0
Ap
r-1
0
M
ay
-1
0
Ju
n-
10
Ju
l-1
0
Au
g-
10
Se
p-
10
O
ct
-1
0
N
ov
-1
0
D
ec
-1
0
Ja
n-
11
Fe
b-
11
M
ar
-1
1
Ap
r-1
1
M
ay
-1
1
Ju
n-
11
Ju
l-1
1
Au
g-
11
Se
p-
11
Monthly CRC incidence
Mean +/- 2 s.d. for
period Jan 10 to Jan 11
Fig. 3 Colorectal cancer incidence in the East of England and
southwest regions combined (data extract October 2012)
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due to the campaign as the increase occurred before the
start of the campaign (from December 2010 to March
2011) [6]. Hence, no significant change in screening uptake
which could be clearly attributed to the campaign was
observed.
Costs
The Department of Health provided the total cost of
running the pilot campaign which was £1.6 million
(£0.22 per person aged 30 or over) [7]. The budgeted
cost for the national campaign (run in January 2012) was
£4.5 million (£0.14 per person aged 30 or over). As this
analysis will make predictions relating to a national
campaign, a cost of £0.14 per person was used. The
model also includes costs associated with additional GP
attendances, CRC treatment costs, and CRC screening
costs. Details of the costs used and their sources are
provided in Tables 2 and 3.
Mathematical model
An existing mathematical model for CRC screening was
adapted for this project [11]. The model captures the nat-
ural history of CRC by representing the progression of pre-
cancerous lesions (adenomas) to cancer and the progression
of cancer through the Dukes’ stages. The model also rep-
resents the current CRC screening program of a biennial
guaiac faecal occult blood test (gFOBT), follow-up of
gFOBT positives with colonoscopy, and colonoscopic
surveillance of high-risk individuals. The model has a
state-transition structure and is built in Microsoft Excel
with Visual Basic macros. Figure 4 illustrates the states
and transitions included within the model. Uncertain model
parameters are estimated using a process of model cali-
bration, which is described in detail elsewhere [12]. Details
of the natural history transition probabilities used in the
model are provided in Table 3. The model takes the per-
spective of the NHS with a life-time horizon.
The modeling assumes that the awareness campaign
results in a change in the probability of a person with
undiagnosed CRC presenting symptomatically at their GP
(as highlighted in Fig. 4). This change in the symptomatic
presentation probabilities is determined so that model
predictions of the change in CRC incidence reflect those
seen following the pilot campaign. The diagnosis of cancer
through symptomatic or chance presentation (non-screen-
detected incidence) is represented in the model using a
transition probability that is dependent on the Dukes’ stage
of the cancer at presentation. As the data on CRC incidence
by stage were inconclusive, the campaign was assumed to
have the same proportional effect on non-screen-detected
incidence for each CRC stage; a 10 % increase for a period
of one month. This means that the stage distribution of the
increase in incidence was the same as the stage distribution
of incidence in the absence of the campaign (Dukes’ stages
A, B, C and D: 11, 25, 36, and 29 %, respectively). The
base case assumes that the campaign results in an increase
in both symptomatic presentation and chance detection.
However, a sensitivity analysis considered a situation
where the increase in incidence was just made up of Dukes’
stages C and D as these stages are more likely to be
associated with symptoms. This represents a scenario in
which the campaign changes the rate of symptomatic pre-
sentation, but not chance detection.
Even though the campaign was assumed to have the
same proportional effect on the presentation rates for CRC
regardless of stage, the additional incidence due to the
campaign corresponds to persons presenting earlier than
they would have in the absence of the campaign and this
earlier presentation results in a change in the stage distri-
bution over the following years. The campaign was
assumed to have the same effect on presentation rates for
Table 2 Model parameters associated with the awareness campaign
Awareness campaign
parameters
Mean Source
Increased presentation
rates stage A
10 % Pilot campaign data [7]
Increased presentation
rates stage B
10 % Pilot campaign data [7]
Increased presentation
rates stage C
10 % Pilot campaign data [7]
Increased presentation
rates stage D
10 % Pilot campaign data [7]
Duration of increase in
presentation rates
(months)
1 Pilot campaign data [7]
Increased screening
uptake rate
0 NHS cancer screening
2012
Cost of campaign per
person
£0.14 Department of Health
2012
Cost of GP visit (12 min
consultation)
£36 Curtis 2010
Average cost of
secondary care
attendance for suspected
lower GI cancer
£200 Costs from NHS reference
costs 2011, probabilities
from Tappenden [24]
Additional GP
attendances per person
0.0014 Pilot campaign data [7]
Additional secondary care
appointments per person
1.52606E-
05
Pilot campaign data [7]
Proportion of additional
visits which are extra
0.5 Assumption
Cost of additional GP and
secondary care
attendances
£0.026 Calculated from other
parameters
Cancer Causes Control (2014) 25:647–658 651
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Table 3 Parameters associated with CRC natural history and screening model
Mean Source
Screening participation and harm parameters
FOBT participation for each screening round 0.54 NHS BCSP data [25]
Proportion completing at least one FOBT screening round 0.63 NHS BCSP data [25]
FOBT participation for a round for those who comply with at least one
FOBT
0.85 Calculated from above parameters
COL follow-up compliance FOBT screening 0.79 NHS BCSP data [25]
COL surveillance compliance 0.83 NHS BCSP data [25]
COL (without polypectomy) perforation rate 0.0 % FS UK screening trial data [26]
COL (with polypectomy) perforation rate 0.3 % Bowel cancer screening pilot 2nd round evaluation
[27]
COL Probability of death following perforation 5.2 % Gatto et al. [28]
COL probability of hospitalization for bleeding 0.3 % FS UK screening trial data [26]
Health-related quality of life parameters
Utility value cancer free 0.80 Ara et al. [29]
Utility value CRC 0.70 Ara et al. [29]
Resource use parameters
gFOBT mean number of tests completed 1.08 Assumption details in [14]
COL repeat test rate 0.07 NHS BCSP data [25]
Cost of gFOBT screen (non-compliers) £2.03 Southern Hub screening costings model [14]
Cost of gFOBT screen (normal result) £3.36 Southern Hub screening costings model [14]
Cost of gFOBT screen (positive result) £11.94 Southern Hub screening costings model [14]
Cost of COL (without polypectomy) £563 NHS ref costs, screening centre estimates [14]
Cost of COL (with polypectomy) £563 NHS ref costs, screening centre estimates [14]
Cost of treating bowel perforation (major surgery) £5,089 NHS reference costs [14]
Cost of admittance for bleeding (overnight stay on medical ward) £278 NHS reference costs [14]
Pathology cost for adenoma/cancer £26 NHS reference costs 08/09, histopathology [14]
Cost of treating colorectal cancer, Dukes’ stage A £1,320–
£8,375
Ranges presented reflect variation according to age
at diagnosis. Generated using model from
Tappenden [24]Cost of treating colorectal cancer, Dukes’ stage B £1,479–
£8,362
Cost of treating colorectal cancer, Dukes’ stage C £1,493–
£13,862
Cost of treating colorectal cancer, Dukes’ stage D £772–£11,198
Test characteristics
gFOBT sensitivity for LR adenomas 0.01 Model calibration [11]
gFOBT sensitivity for HR adenomas 0.12 Model calibration [11]
gFOBT sensitivity for CRC 0.24 Model calibration [11]
gFOBT specificity age 50 0.99 Model calibration [11]
gFOBT specificity age 70 0.97 Model calibration [11]
COL sensitivity for LR adenomas 0.77 Van Rijn et al. [30]
COL sensitivity for HR adenomas 0.98 Van Rijn et al. [30]
COL sensitivity for CRC 0.98 Bressler et al. [31]
COL specificity 1.00 Assumption due to nature of the test
Natural history parameters
Normal epithelium to LR adenomas–age 30 0.021 Model calibration [11]
Normal epithelium to LR adenomas–age 50 0.020 Model calibration [11]
Normal epithelium to LR adenomas–age 70 0.045 Model calibration [11]
Normal epithelium to LR adenomas–age 100 0.011 Model calibration [11]
LR adenomas to high-risk adenomas–age 30 0.009 Model calibration [11]
LR adenomas to high-risk adenomas–age 50 0.008 Model calibration [11]
652 Cancer Causes Control (2014) 25:647–658
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all age groups. The model responds to these adjusted
symptomatic presentation probabilities by predicting
associated changes in time to diagnosis, stage of diagnosis,
and CRC mortality due to the campaign.
The additional colonoscopy activity caused by the
campaign will increase adverse events associated with
colonoscopy such as bowel perforations. The increase in
polypectomies may also prevent some cases of CRC. The
negative impact of additional colonoscopies (such as
bleeding and bowel perforations) may be offset by the
prevention of CRC through the removal of HR adenomas,
so these were considered within a scenario analysis.
Model predictions were generated to reflect a national
campaign as this was thought to be of most relevance for
policy makers. Model predictions for no awareness cam-
paign and an awareness campaign were produced. Predic-
tions reflect changes in costs and QALYs for the lifetime of
the entire current population of England aged over 30 (33
million persons). Predicted total costs were broken down to
include the following: campaign costs, CRC treatment
costs, and costs associated with additional GP attendances
and referrals. Total QALYs, changes in cancer incidence,
cancer stage distribution, and cancer mortality were also
estimated. Future costs and QALYs were discounted at a
rate of 3.5 % per annum in line with current NICE rec-
ommendations [13]. Net monetary benefit was calculated
using a willingness-to-pay threshold of £20 K per QALY.
Cost-effectiveness was reported in terms of cost per QALY
saved.
Sensitivity analyses were undertaken for the following
model parameters: the magnitude, duration and stage dis-
tribution of the short-term increase in incidence due to the
campaign, and the proportion of the increase in GP atten-
dances, which were additional. The model also allowed
comparison between the potential benefits associated with
Table 3 continued
Mean Source
LR adenomas to high-risk adenomas–age 70 0.008 Model calibration [11]
LR adenomas to high-risk adenomas–age 100 0.004 Model calibration [11]
HR adenomas to Dukes’ A CRC–age 30 0.029 Model calibration [11]
HR adenomas to Dukes’ A CRC–age 50 0.025 Model calibration [11]
HR adenomas to Dukes’ A CRC–age 70 0.054 Model calibration [11]
HR adenomas to Dukes’ A CRC–age 100 0.115 Model calibration [11]
Normal epithelium to CRC Dukes’ A 0.00004 Model calibration [11]
Preclinical CRC: Dukes’ Stage A to B 0.51 Model calibration [11]
Preclinical CRC: Dukes’ Stage B to C 0.69 Model calibration [11]
Preclinical CRC: Dukes’ Stage C to D 0.71 Model calibration [11]
Symptomatic presentation with CRC Dukes’ A 0.04 Model calibration [11]
Symptomatic presentation with CRC Dukes’ B 0.18 Model calibration [11]
Symptomatic presentation with CRC Dukes’ C 0.37 Model calibration [11]
Symptomatic presentation with CRC Dukes’ D 0.74 Model calibration [11]
Proportion of cancer incidence classified as proximal 0.38 Cancer Registrations 2007, England [32] ]
Average number of adenomas present in patient with
at least one adenoma
1.90 Winawer et al. [3, 33]
Proportion of advanced adenomas classified as HR adenomas 0.75 FS UK screening trial data [26]
Normal Epithelium
LR adenomas
HR adenomas
Dukes’ A CRC
Dukes’ B CRC
Dukes’ C CRC
Stage D CRC
Dead (CRC)
Dukes’ A CRC clinical
Dukes’ C CRC clinical
Stage D CRC clinical
Dukes’ B CRC clinical
Dead (non-CRC)
Transition affected by the awareness campaign 
(symptomatic presentation transitions)
Model transition
CRC natural history model
CRC=colorectal cancer, LR=low risk, HR=high risk 
Fig. 4 Natural History model diagram
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an awareness campaign and an intervention designed to
increase screening uptake. Probabilistic sensitivity analyses
were undertaken, sampling 1,000 parameter sets to simul-
taneously explore the impact of uncertainty in disease
natural history parameters, test characteristics, costs, and
utility parameters. Distributions for parameters are descri-
bed in the Whyte et al. 2011 report [14].
Results
Model predictions were generated for an awareness cam-
paign causing an increase in presentation rates of 10 % for
1 month. Table 4 shows model predictions broken down to
include incidence by stage and diagnosis route (screen
versus symptomatic detection) and the different compo-
nents of associated costs. A total cost of £5.5 million is
predicted, which comprises campaign costs (£4.5 million),
additional GP consultation costs (£806 K), additional GP
referrals (£50 K), and increased cancer treatment costs
(£95 K).
A campaign is predicted to prevent 66 deaths from CRC
and generate an additional 404 QALYs. It is estimated to
cause an increase in the number of cases of Dukes’ stages
A–C presenting symptomatically and a decrease in the
number of cases of stage D. Overall, an increase in
symptomatic presentation and a small decrease in screen/
surveillance detected cases is predicted. A significant
reduction in CRC-specific deaths was seen, which was due
to the reduction in the number of cases of CRC presenting
in stage D. This reduction in deaths corresponds to an
increase in QALYs gained. There is also a small decrease
in the number of persons dying with undiagnosed CRC.
The incremental cost-effectiveness ratio (ICER) for the
awareness campaign was £13,496 per QALY gained
compared to ‘‘no campaign’’ giving a net monetary benefit
(NMB) of £2.6 million (with a willingness-to-pay threshold
of £20 K per QALY).
Table 5 and Fig. 5 show the results of sensitivity anal-
yses on the increase in presentation rates parameters. Fig-
ure 5 shows the predicted QALY gain for a two-way
sensitivity analyses which varied the duration and magni-
tude of the increase in presentation rates caused by the
campaign. The analysis demonstrates that the results are
highly sensitive to these two parameters with predicted
mortality reductions ranging from 66 (1 month increase in
10 %) to over 800 (6 month increase in 20 %). Similarly,
QALY gain ranged from 202 to 5283 and the ICER ranged
from £1 K to £27 K per QALY. An analysis in which the
increase in presentation rates was restricted to Dukes’
stages C and D was undertaken. In this analysis, an
increase in Dukes’ stages C and D presentation rates of
15 % was applied as this corresponds to an increase in all
stage incidence of 10 %. This analysis showed lower cost-
effectiveness resulting in a gain of 293 QALYs and an
ICER of £21 K. The one-way sensitivity analyses demon-
strated that the uncertainty surrounding the increase in
presentation rate parameters had a big impact on the
effectiveness of the campaign. A scenario analysis in which
Table 4 Model predictions for a CRC awareness campaign resulting
in a 10 % increase in presentation rates for a period of 1 month
Model predictions for the current population of England evaluated
over a lifetime: Change compared to ‘‘No awareness campaign’’
Outcome Mean (from
deterministic
analysis)
95 percentiles from
probabilistic
sensitivity analysis*
CRC incidence–
symptomatic
presentation Dukes’
Stage A
26 (26, 28)
B 52 (49, 53)
C 33 (25, 38)
D -92 (-96, -79)
CRC incidence–
symptomatic
presentation TOTAL
20 (19, 24)
CRC incidence screen/
surveillance detected
Dukes’ Stage A
-0 (0, 0)
B -1 (-2, -1)
C -2 (-3, -2)
D -2 (-3, -1)
CRC incidence–
screening/surveillance
detected TOTAL
-5 (-7, -5)
CRC-specific deaths -66 (-69, -56)
Deaths with undiagnosed
CRC
-14 (-17, -14)
Total costs related to
screening (discounted)
-£3,407 (-4,498, -2,855)
Cancer management (inc.
pathology) costs
(discounted)
£94,443 (88,853, 116,287)
Cost of additional GP
consultations/referrals
(discounted)
£855,716 (855,716, 855,716)
Cost of awareness
campaign (discounted)
£4,499,995 (4,499,995, 4,499,995)
Total cost (discounted) £5,446,745 (5,441,070, 5,468,342)
Total life-years gained
(undiscounted)
991 (833, 1,041)
Total life-years gained
(discounted)
622 (516, 657)
Total QALYs gained
(discounted)
404 (322, 439)
ICER £13,496 (12,407, 16,893)
NMB £2,624,770 (1,001,887, 3,330,998
654 Cancer Causes Control (2014) 25:647–658
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90 % of the increase in GP attendances/referrals was
assumed to be additional as opposed to earlier resulted in
only a small increase in the ICER associated with the
campaign. Probabilistic sensitivity analyses demonstrated
that the uncertainty in natural history parameters, test
characteristics, cost, and utility parameters rates had less
influence on model predictions than variations in the
campaign effect on presentation rates (Figs. 6, 7).
Colonoscopy is associated with a risk of hospitalization
for bleeding of 0.03 % and a negligible risk of perforation
(unless polypectomy is performed). Data on the number of
GP referrals which lead to colonoscopy were not avail-
able, but in an extreme scenario where 100 % receive
Table 5 Sensitivity analyses to explore uncertainty in the increase in presentation rates caused by the campaign: varying the duration,
magnitude, and stage distribution
CRC deaths prevented QALY gain ICER
Magntiude of change in symptomatic presentation rate (% increase)
5 % 10 % 20 % 5 % 10 % 20 % 5 % 10 % 20 %
Campaign causes increase in symptomatic presentation rate for all stages of colorectal cancer
Duration of change in symptomatic presentation rate (months) 1 33 66 131 202 404 807 £26,767 £13,496 £6,861
3 101 202 403 622 1,243 2,487 £8,843 £4,536 £2,383
6 210 419 838 1,296 2,592 5,183 £4,368 £2,301 £1,268
Campaign causes increase in symptomatic presentation rate for Dukes’ stages C and D colorectal cancer
1 14 28 57 98 196 391 £55,210 £27,826 £14,135
3 44 89 177 306 611 1,223 £17,965 £9,205 £4,825
6 94 189 378 651 1,302 2,605 £8,672 £4,560 £2,504
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colonoscopy, the campaign would be predicted to result in 50
cases of hospitalization due to bleeding at a cost of £14 K.
There is a considerable body of evidence demonstrating
the efficacy of campaigns designed to increase screening
uptake [15]. Investment in such campaigns is another route
toward reducing CRC mortality. We considered the two
groups: ‘‘screening never attenders’’ and ‘‘screening
sometimes attenders’’ as defined in the screening reap-
praisal paper [16]. An exploratory analysis estimated that a
reduction in the number of persons in the group ‘‘screening
never attenders’’ by 0.09 % (from 36.55 to 36.52 %) would
result in the same gain in QALYs as was predicted by the
awareness campaign.
Discussion
This study demonstrates that it is possible to use a math-
ematical model together with short-term data from a pilot
CRC awareness campaign to make predictions of both
effectiveness and cost-effectiveness. The campaign was
predicted to reduce CRC mortality and have an ICER of
less than £20,000. However, scenario analyses indicated
that results were highly sensitive to the duration, magni-
tude, and stage distribution of the increase in presentation
rates due to the campaign. The model structure also allows
a comparison of an early awareness campaign and a cam-
paign designed to increase screening uptake. The study also
identified priorities for future awareness campaign evalu-
ations, which are described below.
The data obtained from the pilot campaign should accu-
rately reflect the use of such a campaign in a UK NHS setting.
Hence, this study is of direct relevance for policy making
within the UK. The main weakness of this study is the limited
evidence available on duration of the impact of the aware-
ness campaign. However, the impact of the assumption on
duration was explored within a sensitivity analysis. A
weakness of this analysis is that it was not possible to rep-
resent all possible impacts of an awareness campaign within
the modeling. In 2007, approximately a quarter of cancer
cases in the UK were diagnosed through emergency admis-
sion to hospital [17]. No data were available on the change in
presentation mode (GP versus emergency presentation) as a
result of the campaign. Hence, any potential cost savings as a
result of preventing emergency presentations of CRC was
not incorporated within the modeling. The awareness cam-
paign is designed to increase presentation rates for symptoms
associated with CRC, which may result in the earlier diag-
nosis of other lower GI conditions such as Crohns disease,
ulcerative colitis, inflammatory bowel disease, and piles. No
data were available on changes in diagnosis rates for other
conditions, so any associated costs or QALY differences are
not represented by the model.
This study predicts the effectiveness and cost-effec-
tiveness based on data from an awareness campaign run in
2011. The benefits of such a campaign may well be subject
to change over time as general public awareness changes.
For example, a US study examined the number of diag-
noses made in the month after National Breast Cancer
Awareness Month (NBCAM) saw an increase in diagnoses
during the period when breast cancer advocacy was
expanding rapidly into a nationwide movement, but no
significant change during earlier periods when breast can-
cer advocacy was still a grassroots movement, and in later
periods, when breast cancer advocacy had become a well-
established nationwide cause [18].
Comparison with results from other studies was not
possible as no similar studies which predict the cost-
effectiveness of a CRC awareness campaign were identi-
fied by the literature review. Prior studies have estimated
the cost-effectiveness of patient-directed interventions for
CRC screening (such as a mailed educational reminder for
FOBT screening) are associated with costs ranging from
$15 to $5842 [19]. However, these cannot be compared as
they do not report CRC deaths avoided or cost per QALY.
Implications for policy
Prioritizing between different cancer mortality reduction
strategies is a great challenge for policy makers. Inter-
ventions with the potential to reduce CRC mortality
include the following: awareness campaigns, improve-
ments to the screening program (e.g., different diagnostic
tools [16, 20]), measures to improve uptake [15], inter-
ventions to change lifestyle and risk factors [21], inter-
ventions to improve diagnosis (e.g., cancer prediction
models [22]), and new cancer treatments. This study pro-
vides new evidence on the effectiveness and cost-effec-
tiveness of a CRC awareness campaign to help inform such
decisions. The evaluation of cost-effectiveness as cost
per QALY allows comparison with other interventions
designed to reduced cancer mortality. For example, a cost-
effectiveness analysis of chemoprevention report an ICER
of £23 K for aspirin chemoprevention in the general pop-
ulation compared to screening alone [23]. This study
highlights the potential to compare the cost-effectiveness
of a CRC awareness campaign and a campaign designed to
improve screening uptake. The availability of data on the
cost and effectiveness of a campaign to improve screening
uptake in England would allow such a comparison.
Future research
The data available from the pilot campaign which was
used to generate predictions of efficacy and cost-effec-
tiveness was associated with limitations and considerable
656 Cancer Causes Control (2014) 25:647–658
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uncertainty. A priority for future research is to co-ordinate
and maximize the evaluation and dissemination of efforts
that have already been made to increase cancer awareness.
In particular, comparison with non-intervention regions
and clear reporting of completeness of data and potential
data limitations are essential. To establish the potential
effectiveness and cost-effectiveness of such a campaign
information on ‘‘duration of effect of campaign,’’ ‘‘effect of
campaign on CRC incidence,’’ ‘‘effect of campaign on
emergency presentation rates,’’ and ‘‘effect of campaign by
age’’ are of importance. In addition, data on differential
diagnoses costs associated with emergency presentation
versus two-week wait referrals would be of use for future
modeling exercises. The exploratory analysis into the cost-
effectiveness of a campaign to increase screening uptake
could be developed further if data on the cost and effects
associated with an actual campaign from the UK were
available.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use, dis-
tribution, and reproduction in any medium, provided the original
author(s) and the source are credited.
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